Company Overview and News

 
Here's Why You Should Invest in GNC Holdings (GNC) Right Now

12h zacks
GNC Holdings, Inc. (GNC - Free Report) has been gaining investor confidence on stellar results over an extended period. Year to date, the company’s stock has outperformed its industry. The stock has gained 11.2% against the industry’s 2.2% rise.
MASI GNC ISRG GHDX

5
Will Instruments Drive Intuitive Surgical (ISRG) Q3 Earnings?

15h zacks
Intuitive Surgical Inc (ISRG - Free Report) is expected to release third-quarter 2018 results on Oct 18, after market close. The company expects steady growth in the Instruments and Accessories segment.
MASI BIO.B BIO CTRL BAX ISRG

1
Amedisys to Buy Compassionate Care Hospice, Share Price Down

2018-10-15 zacks
Amedisys, Inc. (AMED - Free Report) recently inked an agreement to buy national hospice care provider —Compassionate Care Hospice. Amedisys is slated to pay $340 million, which includes $50 million in payments related to a tax asset and working capital for acquiring 100% ownership interest in Compassionate Care Hospice. The transaction is expected to close by Feb 1, 2019.
MASI AMED ISRG GHDX

259
Stocks To Watch: Was That A Speed Bump?

2018-10-13 seekingalpha - 5
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
GLBS PERY PSX LCII ABT CRM SHPG CSCO MS AMC COF-P SMPL ISRG SYF DVMT IDA JNJ HON.WI MSFT HLUKF LEVL FTCH APHQF UTHR MTW ADS FB SCL NFLX AXP SKX SU BAC COF-D COF-C COF-F AAPL CCI ELAN HUBB CE SU EB SURF TRIP PVTL GSK EOG SIX JPM PATK SBUX CNTTF KMRFZ CNC CNK WMT NKE SHAK AMZN HON KMI TWTR HCSG GSK TRMB EAF KMR AA DXC CVB EBAY REGN SLB BAC DFS CRON STBA SC UAL GOOGL LTXB AHBIF PENN SCL SLB QCOM WFCNP XLNX PM PG PNK CPB PYPL VMW WGO TLRY USB GS MYL JEC SWI XYF WEED DXC.WI ECL ABT IBM CWH WFC HON BUD C TPR CMCSA THO COF BSVN LECO CGC SNY VLTHF V SCHW HP T MRK SNE DPZ

14
Quest Diagnostics Boosts Health & Wellness, Acquires Provant

2018-10-12 zacks
Quest Diagnostics Incorporated (DGX - Free Report) through its subsidiary Summit Health has acquired the assets of Hooper Holmes, Inc. d/b/a Provant Health. Hooper Holmes is a prominent name in the field of comprehensive workplace well-being and clinical research support services.
MASI CBSH HPHWQ OXFD HPHW CBSHP DGX AMED ISRG HH CBCB

1
QIAGEN Introduces New RNA-seq Library Preparation Solutions

2018-10-12 zacks
QIAGEN N.V. (QGEN - Free Report) recently launched a technology for faster and simpler library preparation of ribonucleic acid, or RNA sequencing for next-generation sequencing (NGS).An integral component of this offering is the QIAseq FastSelect RNA Removal Kit.
MASI CBSH CBSHP AMED ISRG CBCB

108
Fed's Macro Approach To The Economy Is Incorrect - Cramer's Mad Money (10/11/18)

2018-10-12 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, October 11.
NIO PG TTWO LEN IDXX TEL ISRG NWL EXPD INTU AMZN PPG MU TSE AMAT TSLA ADSK CLX

 
Intuitive Surgical (ISRG) Q3 Earnings Preview: What's Shaping Up?

2018-10-11 zacks
The market expects Intuitive Surgical (ISRG - Free Report) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
ISRG

137
Walgreens (WBA) Q4 Earnings Top Estimates, Revenues Lag

2018-10-11 zacks
Walgreens Boots Alliance, Inc. (WBA - Free Report) reported adjusted earnings per share (EPS) of $1.48 for fourth-quarter fiscal 2018, up 12.9% year over year (same at constant exchange rate). The figure surpassed the Zacks Consensus Estimate of $1.44.
MASI RAD WBA AMED ISRG

5
Here's Why You Should Hold on to athenahealth (ATHN) for Now

2018-10-11 zacks
athenahealth, Inc. (ATHN - Free Report) has topped estimates in the trailing four quarters. For the quarters ahead, the company is expected to gain from its solid focus on cloud-based services and a raised guidance for 2018. However, cutthroat competition might pose a threat.
MDRX CERN ISRG ATHN

 
Baxter & ASPEN Launch PN Tools to Boost Clinical Nutrition

2018-10-11 zacks
Baxter International Inc. (BAX - Free Report) and the American Society for Parenteral and Enteral Nutrition (ASPEN) recently launched an educational video series on the appropriate use of parenteral nutrition (PN). Notably, this is part of SmartPN, a collaboration between Baxter ad ASPEN, which came into effect in 2017.
MASI INGN BAX ISRG

 
Is Intuitive Surgical (ISRG) Stock Outpacing Its Medical Peers This Year?

2018-10-11 zacks
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Intuitive Surgical (ISRG - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
ISRG

1
Edwards Begins US CENTERA Study, Reintroduces Valve in Europe

2018-10-09 zacks
Edwards Lifesciences Corporation (EW - Free Report) recently announced the commencement of a study on the company’s self-expanding CENTERA transcatheter valve. The company has started a U.S. pivotal trial on CENTERA for severe, symptomatic aortic stenosis (AS) patients who are at intermediate risk of open-heart surgery.
MASI AMED ISRG EW

4
Here's Why You Should Invest in Boston Scientific Stock Now

2018-10-09 zacks
Boston Scientific Corporation (BSX - Free Report) has been gaining investor confidence on consistently encouraging results. Over the past six months, the company’s share price has outperformed its industry. The stock has gained 27.1% compared with the industry’s 19% rally. Also, the company has outperformed the S&P 500’s 8.7% rise.
MASI BSX AMED ISRG

1
Here's Why You Should Invest in Genomic Health (GHDX) Now

2018-10-09 zacks
Genomic Health, Inc. (GHDX - Free Report) has been gaining investor confidence on stellar results over an extended period. Over the past year, the company’s share price has outperformed its industry. The stock has gained 103.2% against the industry’s 18.6% fall. Also, the company has fared better than the S&P 500’s 13.9% rise.
MASI AMED ISRG GHDX

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ISRG / Intuitive Surgical, Inc. on message board site Silicon Investor.

Intuitive Surgical, Inc. (ISRG) Intuitive Surgical, Inc. (ISRG) Intuitive Surgical, Inc. (ISRG) ISRG - Intuitive Surgical ISRG - Intuitive Surgical ISRG - Intuitive Surgical
ISRG ISRG ISRG
CUSIP: 46120E602